{"product_id":"retatrutide-cagrilintide","title":"Retatrutide + Cagrilintide","description":"\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:0 0 .4em;font-family:inherit;\"\u003eWhat it is\u003c\/p\u003e\n\u003cp style=\"font-size:1.12em;line-height:1.7;margin:0 0 1em;\"\u003eThe most ambitious combination in the catalog: the compound that copies \u003cstrong\u003ethree hormones at once\u003c\/strong\u003e —the most potent published— together with the amylin analog. Four different satiety and energy expenditure signals in a single vial.\u003c\/p\u003e\n\u003cp style=\"font-size:1.02em;line-height:1.7;margin:0 0 1.2em;color:#374151;\"\u003eRetatrutide already presses three keys: two that curb hunger and one that increases energy burn. Cagrilintide adds a fourth, amylin, which is independent of the others and prolongs the feeling of fullness. The idea is to cover energy balance from both sides at once: what comes in and what is spent.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eWhat it is used for\u003c\/p\u003e\n\u003cul style=\"margin:0 0 1.2em;padding-left:0;list-style:none;line-height:1.9;\"\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Research on weight control combining incretins and amylin\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Energy expenditure and thermogenesis, the branch contributed by glucagon\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Satiety targeted through four different signals\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Body recomposition and fat mass\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eHow it is used\u003c\/p\u003e\n\u003cdiv style=\"display:flex;gap:12px;margin:0 0 1.4em;flex-wrap:wrap;\"\u003e\n  \u003cdiv style=\"flex:1;min-width:150px;padding:12px 16px;background:#f6f6f7;border-radius:10px;\"\u003e\n    \u003cdiv style=\"font-size:.72em;text-transform:uppercase;letter-spacing:.08em;color:#9ca3af;margin-bottom:2px;\"\u003eCycle\u003c\/div\u003e\n    \u003cdiv style=\"font-weight:600;\"\u003eContinuous until target\u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003cdiv style=\"flex:1;min-width:150px;padding:12px 16px;background:#f6f6f7;border-radius:10px;\"\u003e\n    \u003cdiv style=\"font-size:.72em;text-transform:uppercase;letter-spacing:.08em;color:#9ca3af;margin-bottom:2px;\"\u003eBreak\u003c\/div\u003e\n    \u003cdiv style=\"font-weight:600;\"\u003eNot required\u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003cdiv style=\"flex:1;min-width:150px;padding:12px 16px;background:#f6f6f7;border-radius:10px;\"\u003e\n    \u003cdiv style=\"font-size:.72em;text-transform:uppercase;letter-spacing:.08em;color:#9ca3af;margin-bottom:2px;\"\u003eRoute\u003c\/div\u003e\n    \u003cdiv style=\"font-weight:600;\"\u003eWeekly subcutaneous\u003c\/div\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eLyophilized powder with both peptides combined. It is reconstituted with bacteriostatic water, swirled without shaking, and stored between 2 and 8 °C. In the literature the components are administered weekly, always with gradual dose escalation \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eWhat has been observed\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;color:#6b7280;font-size:.95em;\"\u003eResults described in the published scientific literature. They are not directions for use or health recommendations.\u003c\/p\u003e\n\u003cul style=\"margin:0 0 1.2em;padding-left:0;list-style:none;line-height:1.9;\"\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Retatrutide achieved a mean weight reduction of \u003cstrong\u003e24.2%\u003c\/strong\u003e at 48 weeks in its phase 2 trial, the highest figure published for an incretin agonist \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  Cagrilintide reached 10.8% as monotherapy in its phase 2, and outperformed daily liraglutide despite being injected once a week \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[2]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  That amylin and incretins add up is not a hypothesis: the combination of cagrilintide with semaglutide reached 20.4% in phase 3, above each component separately \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[3]\u003c\/sup\u003e\n\u003c\/li\u003e\n  \u003cli style=\"padding-left:1.3em;text-indent:-1.3em;margin:0;\"\u003e\n\u003cspan style=\"color:#0099ff;font-weight:700;\"\u003e•\u003c\/span\u003e  For both components, the adverse effects described are mostly digestive, dose-dependent and can be attenuated with slow escalation \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[2]\u003c\/sup\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eHow it works\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eRetatrutide — GIP \/ GLP-1 \/ glucagon triple agonist\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eIt acts simultaneously on all three receptors \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e. The GIP and GLP-1 branches reduce intake; the glucagon branch is associated with greater energy expenditure and mobilization of liver fat, and it is what distinguishes it from dual agonists \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[5]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eCagrilintide — amylin analog\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eA long-acting analog designed to resist degradation \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[4]\u003c\/sup\u003e. It acts on receptors in the area postrema and slows gastric emptying, a pathway independent of incretins \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[2]\u003c\/sup\u003e.\u003c\/p\u003e\n\u003cp style=\"margin:1.1em 0 0.3em;font-weight:600;font-family:inherit;\"\u003eThe rationale for the combination\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.9em;line-height:1.6;\"\u003eFour targets spread across two systems that do not overlap. The precedent of cagrilintide with semaglutide shows that adding amylin to an incretin agonist produces a greater effect than the incretin agonist alone \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[3]\u003c\/sup\u003e; this formulation applies the same rationale to a more potent agonist.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eState of the evidence\u003c\/p\u003e\n\u003cp style=\"margin:0 0 0.7em;padding:10px 14px;background:#f3f4f6;border-radius:8px;font-size:.92em;color:#4b5563;line-height:1.5;\"\u003e\u003cstrong\u003eSolid for each component, nonexistent for the combination.\u003c\/strong\u003e Each of the two peptides has published randomized clinical trials \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[1]\u003c\/sup\u003e\u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[2]\u003c\/sup\u003e, and the principle of combining amylin with an incretin agonist has been validated in phase 3 with another pair \u003csup style=\"color:#0099ff;font-weight:600;\"\u003e[3]\u003c\/sup\u003e. But there is no published study of \u003cem\u003ethis\u003c\/em\u003e specific formulation: it is research material, not a medicine, and its combined profile has not been characterized.\u003c\/p\u003e\n\n\u003cp style=\"margin:1.6em 0 0;padding:12px 14px;background:#f3f4f6;border-radius:8px;font-size:.92em;color:#4b5563;line-height:1.5;\"\u003e⚠️ Product intended exclusively for \u003cstrong\u003eresearch and laboratory use\u003c\/strong\u003e. Not for human or veterinary consumption.\u003c\/p\u003e\n\n\u003cp style=\"font-size:.8em;letter-spacing:.12em;text-transform:uppercase;color:#9ca3af;font-weight:600;margin:1.9em 0 .6em;font-family:inherit;\"\u003eReferences\u003c\/p\u003e\n\u003col style=\"margin:0;padding-left:1.4em;font-size:.86em;color:#6b7280;line-height:1.7;\"\u003e\n  \u003cli\u003eJastreboff AM, et al. \u003cem\u003eTriple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.\u003c\/em\u003e N Engl J Med, 2023. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/37366315\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 37366315\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eLau DCW, et al. \u003cem\u003eOnce-weekly cagrilintide for weight management in people with overweight and obesity: a phase 2 dose-finding trial.\u003c\/em\u003e Lancet, 2021. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34798060\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 34798060\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eGarvey WT, et al. \u003cem\u003eCoadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.\u003c\/em\u003e N Engl J Med, 2025. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40544433\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 40544433\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eKruse T, et al. \u003cem\u003eDevelopment of Cagrilintide, a Long-Acting Amylin Analogue.\u003c\/em\u003e J Med Chem, 2021. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/34288673\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 34288673\u003c\/a\u003e\n\u003c\/li\u003e\n  \u003cli\u003eKatsi V, et al. \u003cem\u003eRetatrutide — A Game Changer in Obesity Pharmacotherapy.\u003c\/em\u003e Biomolecules, 2025. \u003ca href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40563436\/\" target=\"_blank\" rel=\"nofollow noopener\" style=\"color:#0099ff;text-decoration:none;\"\u003ePubMed 40563436\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ol\u003e","brand":"PeptidoBioGenetic","offers":[{"title":"10 mg","offer_id":55126426878281,"sku":"RC10","price":158.0,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1016\/7507\/3865\/files\/retatrutide-cagrilintide-sin-fondo.png?v=1787687109","url":"https:\/\/www.peptidobiogenetic.com\/en-us\/products\/retatrutide-cagrilintide","provider":"PeptidoBioGenetic","version":"1.0","type":"link"}